September 9, 2009
Stem cell drug fails clinical tests
A U.S. drugmaker says its efforts to produce the first drug derived from human stem cells has failed clinical trials.
Osiris Therapeutics of Columbia, Md., announced Tuesday that a pair of clinical trials for its drug Prochymal revealed that it was no more effective than a placebo in treating bone marrow transplant complications, The New York Times reported.
Osiris officials said that while the second clinical trial didn't produce the hoped-for results, it did indicate that Prochymal provided a statistically meaningful benefit for graft-versus-host disease patients in treating their affected livers and gastrointestinal tracts.
Prochymal is having a clear effect in the liver, and that is the most underserved patient population, C. Randal Mills, the company's chief executive, told the newspaper.